Xeris Pharmaceuticals Inc Down 12.99% To $2.80 After Earnings Meet

Xeris Pharmaceuticals Inc (XERS) said before open Wednesday that it lost $0.1 per share in quarter four 2023.

On the revenue line, the company reported $44.4 million, beating estimates by $840 thousand.

In the same quarter a year ago, the company lost $0.1 per share on revenue of $33.1 million.

The stock is down 12.99% to $2.80 after the report.



The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned Xeris Pharmaceuticals Inc a Bearish Sentiment Rank from InvestorsObserver.

Xeris Pharmaceuticals Inc has been a strong performer over the past few months, garnering a high Long-Term Technical Rank by InvestorsObserver of 98, putting Xeris Pharmaceuticals Inc in the top 25% of stocks. The firm was recently trading at a 52-week high of $3.26 on February 15, 2024 and set a 52-week low on March 10, 2023 at $1.13.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.